Arkema Expands Its Polymer Range for the Medical Market with the Introduction of Kynar® MED PVDF
The introduction of Kynar® MED PVDF will enable Arkema to support its customers in developing high performance products within this rapidly growing market sustained by demographic changes (an aging population), an increase in the quality of life in emerging countries, and the development of ever-more-complex medical devices requiring highly specialized materials.
Kynar® MED PVDF resins complement Arkema’s existing range of specialty polyamides developed for the medical market (Pebax® MED, Rilsan® MED, Rilsan Clear® MED, and Rilsamid® MED), offering medical device producers a broad selection of technical properties during their product design phase.
Kynar® MED PVDF resins meet the requirements of the USP Class VI standards and the tests of ISO 10993 parts -4 and -5.
The first resin to be added to the range is Kynar® 720 MED. With excellent resistance to chemicals, UV radiation, and gamma, steam, and ethylene oxide sterilization, this product is a material of choice for the extrusion of medical tubes, injection of flexible parts, and specialized medical packaging.
Arkema is committed to providing polymers with outstanding quality and tailored performance for medical applications, with dedicated production sites for each product. In addition, any change in specifications or manufacturing location for these grades will be communicated to customers 12 months prior to any such change.
In accordance with the Arkema Group’s medical policy, technical polymers outside of the MED range are not permitted by Arkema for use in medical applications.
Kynar® MED resins are available worldwide and are sold by traditional MED technical polymer distributors.